Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501433 · ClinicalTrials.gov registry record · NA
Effects of Nicotinamide Riboside on Metabolism and Vascular Function
A NA study, sponsored by Iowa State University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT03501433: Completed NA study, sponsored by Iowa State University.
NCT03501433 is a NA study that has completed, run by Iowa State University. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03501433, a NA study, has completed, sponsored by Iowa State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.
Primary Outcome
Blood and peripheral blood mononuclear cell (PBMC) levels
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Nicotinamide riboside chloride (Niagen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2019-12-01 |
| Phase | NA |
What the finished NCT03501433 record still lists
NCT03501433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03501433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03501433 about?
NCT03501433 is a clinical study titled "Effects of Nicotinamide Riboside on Metabolism and Vascular Function". The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.
What is the current status of trial NCT03501433?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2018-02-01. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT03501433?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide riboside chloride (Niagen) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03501433?
This trial is sponsored by Iowa State University, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03501433's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI